"No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment

Biol Blood Marrow Transplant. 2014 Apr;20(4):490-4. doi: 10.1016/j.bbmt.2013.12.561. Epub 2013 Dec 18.

Abstract

Washing cord blood (CB) grafts involves product manipulation and may result in cell loss. We investigated double-unit CB transplantation (CBT) using red blood cell (RBC)-depleted units diluted with albumin-dextran in patients with hematologic malignancies. One-hundred thirty-six patients (median age, 43 years; range, 4 to 71; median weight, 69 kilograms (kg); range, 24 to 111) underwent transplantation with a 4/6 to 6/6 HLA-matched graft. Patients ≤ 20 kg were excluded, as they only received washed units. Units were diluted a median of 8 fold to a median volume of 200 mL/unit. The median infused total nucleated cell doses were 2.7 (larger unit) and 2.0 (smaller unit) x 10(7)/kg, respectively, and the median post-thaw recovery was 86%. Units were infused consecutively (median, 45 minutes/unit). While only 17 patients (13%) had no infusion reactions, reactions in the remaining 119 patients were almost exclusively mild-moderate (by CTCAE v4 criteria 12 grade 1, 43 grade 2, 63 grade 3) with only 1 patient (< 1%) having a severe (grade 4) reaction. Moreover, most were easily treated. Grade 2 to 3 hypertension was the most common in 101 (74%) patients. The cumulative incidence of sustained donor-derived neutrophil engraftment was high: 95% in myeloablative and 94% in nonmyeloablative CBT recipients. With appropriate supportive care, double-unit CBT with RBC-depleted grafts infused after albumin-dextran dilution is safe with high rates of engraftment in patients > 20 kg.

Keywords: Cord blood transplantation; Engraftment; Infusion reactions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cord Blood Stem Cell Transplantation / methods*
  • Dextrans / administration & dosage
  • Female
  • Graft Survival*
  • HLA Antigens / immunology
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / therapy*
  • Histocompatibility Testing
  • Humans
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • Pharmaceutical Vehicles / administration & dosage
  • Retrospective Studies
  • Serum Albumin / administration & dosage
  • Transplantation Conditioning*
  • Treatment Outcome

Substances

  • Dextrans
  • HLA Antigens
  • Myeloablative Agonists
  • Pharmaceutical Vehicles
  • Serum Albumin